KOREA WHO
-
-
-
CEO of IM Biologics
Ha Gyong-sik
HK inno.N Veteran Drives IMB-101 Global Trials
-
Last Updated on Apr 30, 2026
-
CEO of IM Biologics
Life Summary
Ha Gyong-sik is the CEO of IM Biologics.
He is focusing on advancing global clinical trials for the core pipeline ‘IMB-101’ while accelerating the expansion of the company’s business into the immuno-oncology field beyond autoimmune diseases.
He was born in May 1973.
He graduated from the Department of Genetic Engineering at Korea University and earned both his master’s and doctoral degrees in Biotechnology from Korea University Graduate School.
He joined CJ CheilJedang, where he worked as a senior researcher at the research institute and in the oncology clinical team and marketing team.
After the pharmaceutical business was spun off, he worked at CJ Healthcare (now HK inno.N) as head of the Protein Group at the Bio Research Center and as head of the Bio Business Development Team.
After CJ Healthcare was acquired by Kolmar Korea and renamed HK inno.N, he served as head of the Bio Research Center.
In 2020, he founded IM Biologics.
He is an expert in antibody drug development with more than 20 years of experience.
He has proven business achievements through large-scale technology transfer.
#IMBiologics #HaGyong-sik #biotechCEO #antibodydrugs #immunotherapy #clinicaltrials #biotechnology #drugdevelopment #HKinnoN #CJHealthcare
He is focusing on advancing global clinical trials for the core pipeline ‘IMB-101’ while accelerating the expansion of the company’s business into the immuno-oncology field beyond autoimmune diseases.
He was born in May 1973.
He graduated from the Department of Genetic Engineering at Korea University and earned both his master’s and doctoral degrees in Biotechnology from Korea University Graduate School.
He joined CJ CheilJedang, where he worked as a senior researcher at the research institute and in the oncology clinical team and marketing team.
After the pharmaceutical business was spun off, he worked at CJ Healthcare (now HK inno.N) as head of the Protein Group at the Bio Research Center and as head of the Bio Business Development Team.
After CJ Healthcare was acquired by Kolmar Korea and renamed HK inno.N, he served as head of the Bio Research Center.
In 2020, he founded IM Biologics.
He is an expert in antibody drug development with more than 20 years of experience.
He has proven business achievements through large-scale technology transfer.
#IMBiologics #HaGyong-sik #biotechCEO #antibodydrugs #immunotherapy #clinicaltrials #biotechnology #drugdevelopment #HKinnoN #CJHealthcare